PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022 - New Market Report

PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022 - New Market Report

New Pharmaceuticals market report from GlobalData: "PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022"

Boston, MA -- (SBWIRE) -- 09/13/2013 -- GlobalData has released its new Country report, "PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022". There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

GlobalData expects the PsO pipeline to begin launching hopefuls in 2015, starting with Novartis' secukinumab and Celgene's apremilast. The following year, Merck's MK-3222, Lilly's ixekizumab, Pfizer's Xeljanz, and Amgen's brodalumab will emerge, thus jamming the PsO market and making it difficult for each drug to gain market share.

View Full Report Details and Table of Contents

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Psoriasis market.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the UK.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Psoriasis - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Psoriasis - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Psoriasis - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Psoriasis - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Psoriasis - China Drug Forecast and Market Analysis to 2022
- PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022
- PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022

Source:

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.